apomorphine archimedes pharma france, solution injectable/pour perfusion
archimedes pharma france sarl - chlorhydrate d'apomorphine - solution - 10 mg - composition pour 1 ml > chlorhydrate d'apomorphine : 10 mg - agonistes dopaminergiques
morphine (chlorhydrate) lavoisier 10 mg/ml, solution injectable en ampoule de 5 ml
laboratoires chaix et du marais - chlorhydrate de morphine - solution - 10,00 mg - composition pour 1 ml de solution injectable > chlorhydrate de morphine : 10,00 mg
morphine renaudin 1 pour cent (50 mg/5 ml), solution injectable
société d'exploitation des laboratoires renaudin - chlorhydrate de morphine - solution - 50 mg - composition pour ampoule > chlorhydrate de morphine : 50 mg
morphine renaudin 2 pour cent (100 mg/5 ml), solution injectable
société d'exploitation des laboratoires renaudin - chlorhydrate de morphine - solution - 100 mg - composition pour une ampoule > chlorhydrate de morphine : 100 mg
sitagliptin / metformin hydrochloride sun
sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabète sucré, type 2 - les médicaments utilisés dans le diabète - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. triple thérapie de combinaison) en complément d'un régime alimentaire et l'exercice chez les patients insuffisamment contrôlés sur leur dose maximale tolérée de metformine et une sulphonylurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
ephydion, comprimé enrobé
cilfa developpement - chlorhydrate d'éthylmorphine - comprimé - 8,000 mg - composition pour un comprimé > chlorhydrate d'éthylmorphine : 8,000 mg > benzoate de sodium : 80,000 mg > grindélia (extrait mou de) : 12,500 mg - antitussif opiace
ephydion, solution buvable
cilfa developpement - chlorhydrate d'éthylmorphine - solution - 0,800 g - composition pour 100 ml > chlorhydrate d'éthylmorphine : 0,800 g > benzoate de sodium : 0,200 g > grindélia (extrait de) (fluide) : 0,400 g - antitussif opiace
apo-go-amp 10 mg/ml sol. inj./perf. s.c. amp.
eg sa-nv - chlorhydrate d'apomorphine 10 mg/ml - solution injectable/pour perfusion - 10 mg/ml - chlorhydrate d'apomorphine 10 mg/ml - apomorphine
apo-go-amp 10 mg/ml sol. inj./perf. s.c. amp.
eg sa-nv - chlorhydrate d'apomorphine 10 mg/ml - solution injectable/pour perfusion - 10 mg/ml - chlorhydrate d'apomorphine 10 mg/ml - apomorphine
sitagliptin / metformin hydrochloride mylan
mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabète sucré, type 2 - les médicaments utilisés dans le diabète - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. triple thérapie de combinaison) en complément d'un régime alimentaire et l'exercice chez les patients insuffisamment contrôlés sur leur dose maximale tolérée de metformine et une sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.